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Introduction
Our understanding of how immune responses are generated, 
propagated and stored as memory is undergoing a radical trans-
formation. Recent groundbreaking studies have demonstrated 
that immune activation, acquisition of effector functions and 
generation of immune memory are coupled with profound 
changes in cellular metabolism. In particular, the transition from 
quiescence to activation is coupled with a significant and pro-
longed upregulation of aerobic glycolysis (Warburg metabolism) 
relative to mitochondrial oxidative phosphorylation (OXPHOS). 
This metabolic reprogramming to aerobic glycolysis is neces-
sary for both innate and adaptive immune functions. Further, 
the development of long-lived central memory T cells requires a 
metabolic switch back to mitochondrial OXPHOS or fatty acid 
oxidation energy production. Since robust antitumor memory 
T-cell development is correlated with cancer regression, these 
new mechanistic details pertaining to the metabolic require-
ments of T-cell activation and memory T-cell development hold 
*Correspondence to: T. Kevin Howcroft; Email: Howcrofk@mail.nih.gov
Submitted: 12/21/12; Accepted: 01/15/13
http://dx.doi.org/10.4161/cbt.23616
A Division of Cancer Biology, nCi-sponsored workshop 
Metabolic Reprogramming of the immune Response in the 
Tumor Microenvironment was held october 2nd, 2012 in 
Bethesda, MD. The purpose of the workshop was to bring 
together cancer cell biologists and immunologists to explore 
the mechanistic relationships between the metabolic pathways 
used by cancer cells and antitumor immune cells and how this 
information could be used to improve cancer immunotherapy. 
At the conclusion of the workshop a general discussion 
focused on defining the major challenges and opportunities 
concerning the impact of metabolism on antitumor immunity 
and cancer immunotherapy as well as what tools, technologies, 
resources or community efforts are required to accelerate 
research in this area. overall, future studies need to consider 
how cancer cell metabolic pathways differ from activated 
lymphocytes in order to define a therapeutic window for 
cancer therapy. Further, studies aimed at reprogramming 
the metabolic qualities of T cells with the goal of improving 
immunotherapy were considered a promising avenue.
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promise to dramatically alter how immune responses are evoked 
by manipulation of the metabolic machinery. The principal goal 
of this workshop was to catalyze further progress in understand-
ing the role of cellular metabolism in achieving effective antitu-
mor immunity.
Opening talks addressed the variety of metabolic platforms 
observed in cancers, the nutrient uptake and metabolic pathways 
that support cancer cell growth and technologies to visualize and 
target cancer cell vulnerabilities. Matthew Vander Heiden (MIT) 
evaluated the causes and consequences of the metabolic switch 
from mitochondrial respiration to aerobic glycolysis in proliferat-
ing cells including cancer cells and activated immune cells. A pre-
vailing thought is that this metabolic switch has less to do with 
ATP production than with how proliferating cells acquire the 
biosynthetic precursors to generate the building blocks (proteins, 
lipids and nucleotides) to fuel cell expansion. Cancer cells are 
capable of utilizing a variety of nutrient substrates. Both substrate 
selection and the microenvironment contribute to determining a 
cell’s metabolic phenotype. For example, although cancer cells 
synthesize lipids from multiple carbon sources including glucose 
and glutamine, glutamine is the principal source under hypoxic 
conditions. Thus, one characteristic of rapidly proliferating cells 
is metabolic plasticity. Given that tumors are characterized as 
having a poor blood supply, such metabolic plasticity would allow 
cancer cells to utilize alternative nutrient sources to support their 
biosynthetic needs. Glucose is a major substrate for most cells 
and is regulated by pyruvate kinase (PK). Most cells express one 
of two major PK isoforms: a highly active PK-M1 tetramer or less 
active PK-M2 monomer. Expression of low activity PK-M2 gen-
erates glycolytic intermediates, such as lactate, and is permissive 
for tumor growth. In contrast, PK-M1 neither supports prolifera-
tion nor generates much lactate, and overexpression of PK-M1 in 
tumor cell lines suppresses tumor growth in vivo in mice.1
Douglas Green (St. Jude Children’s Research Institute) 
continued the theme of how cancer cells support the energy 
and biosynthetic demands of cellular proliferation focusing on 
macroautophagy. Both phagocytosis and autophagy are ancient 
biological processes that likely co-evolved to cope with vari-
ous metabolic or immune-mediated environmental stressors. 
Therefore, it shouldn’t be surprising that some components of the 
phagocytic and autophagic pathways are shared. A novel mecha-
nism of autophagy-associated phagocytosis was presented that 
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metabolism in regulating T-cell proliferation and differentiation. 
The glucose transporter family is comprised of 14 member, with 
Glut1 serving as the principal glucose transporter. T cells pri-
marily express Glut1 and Glut3, although Glut6 and Glut8 are 
also expressed. However, upon activation T cells switch to pre-
dominantly Glut1, commensurate with increased glucose uptake. 
Microarray analyses have also revealed that each T-cell subset is 
metabolically distinct. Whereas activated Th1, Th2 and Th17 
subsets are highly glycolytic, Treg utilize a more oxidative metab-
olism with lipids serving as a principal fuel.4 These metabolic 
distinctions may allow a new understanding and approaches to 
manipulate immunity in vitro and in vivo.
Erika L. Pearce (Washington University School of Medicine) 
presented studies supporting a critical need to reassess the basic 
metabolic requirements for T-cell proliferation, survival and 
effector function. Numerous studies have demonstrated that 
activated T cells dramatically increase glucose uptake and lac-
tate production, indicating that aerobic glycolysis is engaged. 
However, oxygen consumption is also increased under activat-
ing conditions. These findings suggest that T cells engage both 
OXPHOS and Warburg metabolism during activation.5 Further, 
although activated cells switch to Warburg metabolism, presum-
ably to support cell expansion, dendritic cells and macrophages 
also switch to Warburg metabolism upon activation even though 
they do not proliferate. This observation suggests that the con-
ventional interpretation that Warburg metabolism is required 
to support the bioenergetic demands of proliferation is not fully 
correct. Thus, the metabolic requirements for T-cell activation, 
expansion and effector function need to be reevaluated.
Jonathan Powell (Johns Hopkins School of Medicine) dis-
cussed the role of the serine/threonine protein kinase mTOR 
in regulating T-cell development. mTOR regulates nutrient and 
hormone-sensitive signaling pathways and has been implicated in 
integrating signals from the microenvironment to instruct T-cell 
differentiation and effector development programs. Previous 
studies using genetically engineered mouse models have shown 
that mTORC1 and mTORC2 selectively regulate CD4+ T-cell 
differentiation. The development of Th1 and Th17 cells is depen-
dent on mTORC1. In contrast, mTORC2 is necessary for the dif-
ferentiation of Th2 cells. When either mTORC1 and mTORC2 
complexes are genetically eliminated or mTOR is pharmacologi-
cally blocked, the default differentiation pathway is toward Treg 
cells. The downstream targets of mTORC1 and mTORC2 that 
regulate CD4+ T-cell differentiation have not been identified, but 
these data suggest that metabolic manipulation could skew the 
immune response.6 Thus, an emerging concept is that metabolic 
considerations play a critical role in determining the developmen-
tal outcome subsequent to lymphocyte activation.
Edward J. Pearce (Washington University School of Medicine) 
discussed the role of mTOR in dendritic cell (DC) survival and 
activation. Toll-like receptor (TLR) agonists activate DCs and 
upregulate the expression of co-stimulatory receptors, antigen 
processing and presenting machinery, cytokines and chemokines. 
This fundamental process is also accompanied by increased 
glucose uptake and an increase in aerobic glycolysis. The switch 
to glycolysis in activated DCs is also accompanied by a marked 
autophagy-associated phagocytosis plays a role in reprocessing 
protein aggregates, cell fragments or corpses to provide energy 
and biosynthetic precursors for proliferating cells is not clear. 
However, processing these components down to simple metabo-
lites would provide all the building blocks required by growing 
cells.
Brian Altman (University of Pennsylvania) focused on the role 
of the transcription factor c-Myc in regulating cell growth and 
metabolism. Myc stands at the crossroads of nutrient accumula-
tion and generation of biomass through its regulation of genes 
involved in cell growth and differentiation. Recent metabolic 
profiling has suggested flexibility in how cancer cells utilize dif-
ferent metabolic pathways. Under normoxic conditions, Burkitt 
lymphoma cells expressing high c-Myc levels, primarily utilize 
glutamine. However, under hypoxia, glucose metabolism goes 
up, suggesting that cancer cells have some flexibility in how they 
can process nutrients based upon c-Myc levels and the availability 
of oxygen in the microenvironment.2 Taken together, these stud-
ies suggest a framework to consider how metabolism is regulated 
to support various cell functions and will inform future studies 
targeting metabolism for therapy.
Ralph J. DeBerardinis (UT-Southwestern Medical Center) 
described approaches utilizing mass spectrometry and NMR 
spectroscopy to track metabolic pathway choice in living tissues. 
Metabolic flux analysis of human lung cancer cell lines in vitro 
identified at least three different metabolic platforms that enable 
high growth rates in culture: glutamine-dependent anaplero-
sis, glutamine-dependent reductive carboxylation and glucose-
dependent anaplerosis. These data reinforce the concept that 
there are numerous metabolic platforms that can support cancer 
cell growth in culture and imply that determining which of these 
pathways are active in vivo will greatly improve the chances for 
successful metabolic cancer therapies.
Caius Radu (UCLA) highlighted the de novo and nucleoside 
salvage pathways used by proliferating cells, including cancer 
cells and lymphocytes, to generate the deoxyribonucleotide tri-
phosphate (dNTP) pools necessary to support DNA replication 
and repair. Both pathways can be imaged using positron emission 
tomography (PET) probes for non-invasive imaging of nucleotide 
metabolism at a whole body level in mice and humans.3 While 
both de novo and nucleoside salvage pathways generate dNTPs, 
their precise contributions to the expansion of dNTP pools 
occurring during T-cell development and activation are yet to be 
defined. It is also unknown whether there are differences between 
proliferating T lymphocytes and cancer cells. Elucidating these 
aspects would contribute to a broader understanding of how 
dividing cells regulate the metabolic flux through the de novo 
and nucleoside salvage pathways and how these two biosynthetic 
pathways can be modulated therapeutically to induce synthetic 
lethality in hematological malignancies and other cancers.
Next, the relationship between metabolism and lymphocyte 
activation, expansion and effector function was explored. The 
role of the central effector molecule, mTOR, in regulating the 
glycolytic shift to support lymphocyte expansion and ability to 
augment antitumor immunity were addressed. Jeffrey Rathmell 
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autologous tumor infiltrating lymphocytes (TILs) or geneti-
cally engineered T cells that are expanded ex vivo and adoptively 
transferred back to the patient. There has been intense interest in 
defining the specific qualities of transferred T cells that produce 
a complete response vs. those that generate no response or a par-
tial response. The most important quality is that T cells persist 
in vivo after adoptive transfer. Although effector T cells lose the 
potential for self-renewal and inevitably senesce, naïve and mem-
ory T cells possess the capacity for self-renewal. Thus, although 
short-lived T effector cells may be efficient cytotoxic killers, the 
long-term therapeutic efficacy of adoptively transferred cells 
resides in the naïve and memory pool. Consistent with this obser-
vation, inhibiting the glycolytic switch with 2-deoxy-d-glucose 
(2DG) prevented senescence and led to greater survival advan-
tage of adoptively transferred T cells in vivo.9 These findings 
inform a novel approach whereby if T cell metabolism could be 
reprogrammed to be less glycolytic during expansion the capac-
ity for self-renewal would be preserved in vivo. Future studies 
will focus on reprogramming the metabolic qualities of T cells 
in adoptive cellular immunotherapy, with the goal of generating 
long-lived antitumor T cells.
At the conclusion of the workshop, a general discussion 
focused on defining the major challenges and opportunities con-
cerning the impact of metabolism on antitumor immunity and 
cancer immunotherapy and what tools, technologies and com-
munity resources are required to accelerate research in this area. 
Overall, future studies need to consider how cancer cell metabolic 
pathways differ from activated lymphocytes in order to define the 
therapeutic window to improve immunotherapy.
Major Challenges and Opportunities
• There is a critical need to assess the crosstalk between the differ-
ent metabolic platforms that may be operating in any given cell 
and to integrate those assessments to generate a more complete 
metabolic profile at the single cell level.
• The relative contributions of biosynthetic molecules taken-
up from the environment vs. those generated de novo and how 
these pathways affect cancer progression need to be determined.
• The relationship between metabolism or different metabolic 
platforms and self-renewal capacity need to be determined.
• A better understanding of how the metabolic environment 
(or nutrient repertoire) in normal tissues, immune tissues and in 
the setting of pathology (in tumors) affects immune cell develop-
ment and/or effector function is needed.
• Studies to elucidate how specific metabolites affect various 
immune states such as activation, anergy, development of long-
lived memory cells vs. short-lived effector cells and homing to 
their proper niche are needed.
• The consequences of metabolic interventions on immune 
cell growth and effector functions need to be fully understood.
Tools, Technologies and Community Resources
• New instrumentation and novel approaches are needed to parse 
the metabolic heterogeneity of tissues in situ and establish the 
increase in the expression of the inducible form of nitrate oxide 
synthase (iNOS) and generation of nitric oxide (NO). The NO 
creates an anaerobic environment that cripples mitochondria and 
inhibits OXPHOS. Because OXPHOS is inhibited in activated 
DCs, these cells are highly glucose dependent and short-lived. 
Inhibiting the glycolytic switch, by adding rapamycin, augments 
the ability of DCs to activate T cells. In the presence of rapamycin, 
DCs rely on OXPHOS to serve their energy demands and do 
not upregulate iNOS nor generate NO. Thus, in the presence 
of rapamycin, NO production is decreased and mitochondrial 
function is maintained. Consequently, TLR-activated monocyte-
derived DCs treated with mTOR inhibitors are long-lived and 
capable of interchangeably using different substrates to support 
their metabolic needs.7 These findings define mTOR as a 
molecular target for augmenting DC survival and activation.
Rafi Ahmed (Emory Vaccine Center) examined the role of 
mTOR in regulating B-cell responses. Rapamycin treatment 
led to a greater than 10-fold inhibition of the primary antibody 
response to acute infection with lymphocytic choriomeningi-
tis virus (LCMV). Germinal center formation was decreased 
and both plasma and memory B cells were reduced. T follicu-
lar helper (Tfh) cells provide primary help to B cells and are 
required for germinal center formation. Paradoxically, Tfh cell-
specific knockdown of mTOR promoted Tfh cell development. 
However, the germinal center response to LCMV challenge was 
rescued using rapamycin-insensitive B cells suggesting that dur-
ing a primary response, rapamycin acts to inhibit B-cell prolif-
eration which impairs the differentiation of naïve CD4 T cells 
into Tfh cells and reduces germinal center formation. However, 
giving rapamycin 90 d after LCMV challenge had no effect indi-
cating that recall responses are not affected by rapamycin. Thus, 
mTOR plays an important role in regulating the proliferation, 
longevity and development of B-cell immune responses.
Doreen Cantrell (University of Dundee) detailed how mTOR 
serves as a central regulator of cytotoxic T lymphocyte (CTL) 
function. Whole cell proteomic analysis of CTL using mass 
spectrometry identified 5,000–6,000 proteins in T cells whose 
expression is changed in the presence of rapamycin. Rapamycin-
treated T cells downregulate expression of glucose transporters 
Glut1 and Glut3 and glycolytic enzymes whereas proteins 
involved in the TCA cycle and mitochondrial respiration were 
increased. Expression of CCR7 and CD62L which regulate 
the migration of naïve T cells to lymphoid tissue is restored by 
rapamycin in effector CTL, permitting them to home back to 
secondary lymphoid tissues where they are not normally found. 
Thus, rapamycin treatment reprograms T-cell metabolism at 
multiple levels. It is likely that the mTOR pathway controls T-cell 
metabolism and trafficking via regulation of HIF1α. HIF1α 
plays a critical role in regulating glucose metabolism, expression 
of cytolytic effector molecules and chemokine and adhesion 
receptors that control migration.8
Nicholas Restifo (NCI) discussed approaches whereby repro-
gramming of the metabolic qualities of T cells would lead to 
improved antitumor immunotherapies. Adoptive T-cell immu-
notherapy has the potential for complete eradication of tumor 
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metabolic changes that are occurring at the single cell level in 
vivo.
• Improved methods and approaches need to be developed to 
assess how the metabolic characteristics of the tumor microenvi-
ronment affect the antitumor immune response.
• Improved methods and approaches are required to address 
whether reported symbioses or competition for metabolite pools 
actually occur in the tumor microenvironment in vivo.
• There is a need for computational models to better under-
stand which metabolic pathways are hard-wired and when 
perturbed lead to cell death and which are flexible and can be 
experimentally manipulated.
• There is a critical need to develop small molecule inhibitors 
of glycolysis, FAO and other metabolic pathways for therapeutic 
intervention.
• Lastly, a comprehensive analysis of the metabolic hetero-
geneity (metabolic flux/metabolomics) of the different immune 
subsets and a full description of the functional consequences 
of differential utilization of metabolic pathways in supporting 
immune cell differentiation is needed.
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